News
The main asset in Biogen's $1.8bn takeover of HI-Bio, anti-CD38 drug felzartamab, delivers a positive phase 2 readout in rare disease IgAN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback